Iridex says two-year study shows MicroPulse TLT lowers intraocular pressure in early-to-advanced glaucoma
Bitget2026/10/12 11:00- IRIDEX highlighted publication of a two-year independent retrospective study on MicroPulse transscleral laser therapy for primary glaucoma.
- Results were presented as already published in the International Journal of Ophthalmology, not flagged for a future medical meeting.
- Study reported sustained eye-pressure control with a lower reliance on medications across early to advanced disease stages.
- Outcomes indicated high treatment success with no reported safety issues or vision loss during follow-up.
- Findings support positioning MicroPulse TLT earlier in the glaucoma treatment pathway, potentially expanding the addressable market for Cyclo G6 systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Justin Sun Expects a Drop in Bitcoin — Details of the One-Hour Meeting Have Emerged
From "selling subscriptions" to "selling results": Adobe (ADBE.US) experiments with weekly billing for Acrobat, BTIG says growth sustainability remains to be verified
At the MAX conference held last week, Adobe unveiled new Agentic AI tools and previewed the upcoming local MCP (Model Context Protocol) integration. This feature will allow creators to directly access third-party agents within Photoshop, Illustrator, Premiere, and After Effects.
AI investment boom leads to job growth only at construction sites
Crypto prices
More
